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As the prevalence of lipoprotein abnormalities in adolescents is increasing dramatically, the 
identification of relevant risk factors is a major public health challenge. The aim of this study was to 
investigate whether a family history of diabetes could be a risk factor for lipid abnormalities in healthy 
individuals. This study is a cross-sectional case control study. 179 men and women were studied in two 
equal-member groups (with diabetic parents' background and without any diabetic sibling). Both 
groups matched in body mass index (BMI), age and sex. The serum concentration of oxidized-low 
density lipoprotein (LDL), Apo B100 and insulin were measured by enzyme linked immunosorbant 
assay technique and TG, Chol, HDL-C, FBS and GTT by enzymatic methods. The LDL-C level was 
calculated using the Friedewald formula. The results show that there were no significant variation in the 
amount of plasma FBS, GTT, Cho, TG, LDL and HDL between the two groups, whereas a significant 
increase was found in the amount of insulin (P = 0.02), Apo B100 (P = 0.001), OX-LDL (P = 0.001) and 
HOMA-IR (P = 0.03) in the case group as compared to the control group. We conclude that a family 
history of diabetic parents can lead to lipid parameters abnormalities and CVD risk factor via 
aggregation of inherited defected genes. 
 





Lipoprotein abnormalities significantly contribute to the 
risk of developing (cardio vascular disease) CVD. The 
early cardiovascular risk factors precede the develop-
ment of CVD in adolescence (Järvisalo et al., 2002; 
Krantz et al., 2004; Relimpio et al., 2002). As the 
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adolescents is increasing dramatically, the identification 
of relevant risk factor is a major public health challenge. 
The U.S. National Cholesterol Education Program 
(NCEP) recommends that to start treatment of CVD, 
medicine should be based on cholesterol levels and the 
number of risk factors. Having a male sibling, who had 
heart disease before 55 years old; or a female sibling, 
with heart disease before 65 years old is a major risk 
factor for CVD (Grundy et al., 2004). 
Many families with familial combined hyperlipidemia 
(FCHL) have glucose intolerance and insulin resistance 
(Brouwers et al., 2010) and the expression of syndrome 
X appears to have a familial basis, although, the 
identification of gene responsible for syndrome X has 
proven difficult because of its etiologic heterogeneity and 





al., 1990; Ericksson et al., 1989; Ho et al., 1990; Xiang et 
al., 2001). More recently, clustering of hypertension and 
insulin resistance in families was accounted for, in part, 
by heritable factors both associated with and independent 
of body mass index (Xiang et al., 2001).  
The association of type 2 diabetes and lipoprotein 
abnormalities such as elevated Apo B100 has been 
proved by Relimpio et al. (2002). Nakhjavani et al. (2009) 
have reported a significant increase of plasma oxidised-
LDL in patients with diabetes as compared to normal 
subjects (Nakhjavani et al., 2009). Family history of 
diabetes as a risk factor for these lipoprotein abnor-
malities can be attributed to a new candidate for major 
gene effects. 
We hypothesized that a background of diabetic parents 
can lead to lipid parameters abnormalities and CVD risk 
factor via aggregation of inherited defected genes. So for 
the first time we conducted this study to investigate that a 
family history of diabetes is a risk factor for lipid 
abnormalities in healthy individuals. 
 
 
MATERIALS AND METHODS 
 
This study is a cross-sectional case control study. In general, 179 
men and women were studied in two groups (treatment and the 
control group), 41 healthy men and 49 healthy women, 40.55 ± 9.63 
years old with a first degree diabetic patient who had been referred 
to Abolfazl Specialized Clinic were selected for this study. Control 
group included 49 men and 40 women 41.37 ± 9.47 year old 
without any history of diabetic parents. Inclusion criteria for both 
groups were based on (FBS < 110 mg/dl and GTT < 140 mg/dl). 
Two groups matched in body mass index (BMI), age and sex and 
the questionnaire developed for all of them were completed by the 
interviewer. 
They were excluded if they had a recent history (within 6 months) 
of myocardial infarction or stroke, significant liver or renal disease 
(plasma creatinine > 130 µmol L-1), microproteinuria, thyroid 
disorders, neoplasm, diabetes and hypertension. They had not 
taken contraceptives, glycocorticoids, ovulation stimulation drugs, 
antihypertensive, oral hypoglycemic, weight lose, estrogens or anti-
androgens medications. All patients fulfilled the following criteria: 
Fasting blood sugar (FBS) < 110 mg/dl, BMI <30 kg/m² and GTT 
<140 mg/dl. The study was approved by the Ethics Committee of 
the Medical Sciences of Bushehr University and the reported 
investigations were carried out in accordance with the principles of 
the Declaration of Helsinki as revised in 2000. Also, the participants 
in the project have given written informed consent. 
Venous blood samples were taken between 8 and 9 a.m. Serum 
was obtained from the blood samples and was centrifuged at 3000 
g for 15 min at 4°C. Immediately after centrifugation, the sera 
samples were frozen and stored at –80°C for a period not more 
than 8 weeks. 
All measurements were carried out at the Research Laboratory of 
the Persian Gulf Tropical Medicine Research Center, Bushehr 
University of Medical Sciences, Bushehr, I. R. Iran. FBS was 
measured by the glucose-oxidase method of Pars Azmoon-co, Iran 
(intra- and interassay coefficients of variation (CVs) were 3.5 and 
3.0%, respectively). The TG, T-Chol and HDL-C levels were 
determined by using cholesterol oxidase phenol, Pars Azmoon-co, 
Iran, on an Autoanalyzer Vital Scientific Selectra 2 (Spankeren, the 
Netherlands) (intra-and interassay CVs were 2.0 and 2.6% for TC, 
and intra-and interassay CVs were 1.5 and 1.9% for HDL-C 
respectively). The LDL-C level was calculated using the Friedewald  




formula. Apo B-100 was determined by using the enzyme linked 
immunosorbant assay technique (ELISA), Cayman chemical co, 
USA (intra-and interassay CVs were 3.5 and 4.2%, respectively). 
The plasma concentration of oxidized LDL-c was measured by 
(ELISA), Assaypro co (intra- and interassay coefficients of variation 
(CVs) were 3.5 and 3.0%, respectively). The plasma insulin (intra-
and interassay CVs 2.1 and 3.7%) were achieved by (ELISA). The 
insulin kit is the brand of DRG German Company. The insulin 
resistance was estimated by HOMA- IR. HOMA-IR was obtained by 




Weight and height was measured by using stadiometer standard 
techniques. The body mass index (BMI) was calculated by kg 







Statistical analysis of the data was performed using SPSS statistical 
software version 11.5. All results were express as mean plus/minus 
standard deviation. The single sample Kolmogrov-Smirnov test was 
used to estimate the variables’ distribution characteristics. Simple 
independent student T-test was used to compare baseline data. 
The differences were compared between the 2 groups with 
ANCOVA. With a calculated sample size of 179 persons with 
diabetic parents' background and without any diabetic sibling, the 
study will have power of 80.5% to yield a statistically significant 
result between these two groups. Two-tailed probability value of P < 
0.05 was considered as statistically significant. 
 
 
RESULTS AND DISCUSSION 
 
179 assigned subjects completed the study. The charac-
teristics of the patients confirmed that the groups were 
well matched for all entry criteria (Table 1). The result 
from this study shows that there is no significant variation 
in the amount of plasma FBS, GTT, Cho, TG, LDL-C and 
HDL-C in case and control groups. There was a 
significant increase in the amount of insulin (P = 0.02), 
Apo B100 (P = 0.001), oxidized -LDL (P = 0.001) and 
HOMA-IR (P =0.03) in the case group as compared to the 
control group (Table 2). 
The findings in this study indicate a significant increase 
of Apo B100 in subjects with diabetic parents when 
compared with individuals without background of 
diabetes. Apo B100 is abundant in LDL and VLDL lipo-
protein particles. The breakdown and reformation of 
these lipoproteins in liver and serum are interlinked via 
several steps that often require the action of enzymes, 
one of which is lipoprotein lipase (LPL). Several single 
nucleotide polymorphisms (SNP) have been found within 
the LPL gene (Ma et al., 2003). In a study on 386 type 2 
diabetic patients, a correlation was found between the 
presence/severity of microalbuminuria and genetic 
variants of LPL (Mattu et al., 2002). Miyashita and et al. 
(2002) compared the levels of LPL in the blood of 40 type 
2 diabetic patients and a group of healthy individuals prior  
to heparin injection (Miyashita et al., 2002).  The  findings 




Table 1. Baseline demographic characteristics of the subjects (n=179) (means ±SD). 
 
Characteristic Control group (n = 89) Patient group (n = 90) 
Age (years) 41.37±9.47 40.55±9.63 
Women 40 49 
men 49 41 
Weight (kg) 74.32±14.75 75.92±13.43 
Height (cm) 166.89±8.87 165.88±9.31 
BMI (kg/m
2
) 26.52±4.24 27.57±4.25 
WHR 0.91±0.17 0.90 ±0.14 
 




Table 2. Mean ±SD concentration in variables in case and control groups. 
 
Characteristic Control group Case group 
Apo-B100 (µg/ml) 4.06±3.72 7.80±6.22
#
 
Oxidized-LDL (units/ml) 4.9±4.41 5.59±2.68
#
 
Insulin (µIU/ml) 6.56(5.03-10.18) 8.75(5.25-16.68)* 
Triglyceride (mg/dl) 155.52±75.00 155.51±82.3 
Cholesterol (mg/dl) 196.92±37.24 198.54±36.85 
HDL-C (mg/dl) 45.44±11,65 43.00±10.38 
LDL-C (mg/dl) 120.04±32.44 121.01±31.55 
FBS (mg/dl) 79.77±10.46 80.50±8.56 
GTT (mg/dl) 92.03±16.65 92.17±15.68 
HOMA-IR 1.29(0.98-1.93) 1.82(1.05-3.06)* 
 
Data is presented as mean ±SD, except for insulin and HOMA-IR [medians (interquartile 
ranges)]. Apo-B100: apolipoprotein B100, FBS: fasting blood sugar, GTT: glucose tolerance 
test, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, 




of their study showed a significant decrease in the 
amount of LPL in the type 2 diabetes patients as 
compare to healthy individuals. This polymorphism was 
further found by Ma et al. (2003) in 785 Chinese subjects, 
of which about 60% had been diagnosed with type 2 
diabetes (Ma et al., 2003). 
Most recently, SNPs of LPL gene were investigated in 
Mexican Americans with insulin resistance (Goodarzi et 
al., 2004). These nuclutiod polymorphisms were inherited 
together on the same chromosome (haplotypes) which is 
associated with insulin resistance. Insulin resistance is a 
pathophysiological determinant in patients with type 2 
diabetes. Of note, these haplotypes were also associated 
with coronary artery disease, suggesting that LPL may 
acts as a genetic link between diabetes and athero-
sclerosis (Goodarzi et al., 2003). Inherited LPL abnor-
malities raise the levels of free fatty acids in plasma, 
increase the flux of free fatty acids into the liver, and 
enhance production of Apo B100. In addition, elevated 
serum insulin may promote reduced retention of free fatty 
acids by adipocytes. The data of our study showed a 
significant increase of insulin concentration in individuals 
with diabetic parents as compared to subjects without 
first degree family history of diabetes mellitus. 
We hypothesized that both LPL abnormalities and 
insulin resistance lead to increased flux of free fatty acids 
into the liver, decreased proteolysis and enhanced 
production of Apo B100. 
Other abnormalities that can aggregate in children of 
diabetic individuals are defect in expression of PPRY 
gene. PPRY is a member of the nuclear hormone 
receptor super-family of transcription factors. It is 
abundant in adipose tissue and plays a key role in fat cell 
differentiation. To date, several genes have been 
identified as being direct targets for PPARY, including 
LPL, fatty acid transport protein and acetyl-CoA-synthase 
(Arner, 2003). The variant of the PPAR receptor inherited 
may affect the risk of obesity or developing type 2 
diabetes (Stumvoll and Haring, 2002). 
In one study conducted by Muler et al. (2003), Pima 
Indians of Arizona for variations in PPARY were screen-
ed. Type 2 diabetes is particularly common among this 
population. Several new SNPs were identified, many in 
the promoter region of the PPARY gene (Muller et al., 
2003).  
Our findings indicate significant elevated oxidized LDL 
in case group as compared to control group. Of note, the 





in lipid metabolism cascade, such as LPL, CETP and 
hepatic lipase are defected in diabetic individuals. In 
nondiabetic children with diabetic parents, defected 
inherited gene for these enzymes can modulate the 
expression of small, dance LDL. This particle has a 
prolonged residence time in plasma, and because of 
decreased interaction with the LDL receptor, it is more 
susceptible to oxidation.  
In our study, a significant increase in insulin resistance 
has been seen in the subjects with diabetic parents in 
comparison to those without family history of diabetes. In 
accordance with our results, Carantani et al. (1998) 
observed a significant relationship between insulin 
resistance and oxi- LDL in a group of nondiabetic patients 
(Carantoni et al., 1998). Glyan et al. (1996) have recently 
raised the possibility of a pro-oxidant action of insulin in 
vivo by demonstrating a consistent free radical-scavenger 






In conclusion, we found that a background of diabetic 
parents was associated
 
with a significantly increased Apo 
B100 and oxidized-LDL in healthy individuals. However, 
observational studies do not prove hypotheses and can 
only suggest the potential mechanisms of action. We now 
urgently need data from the relative contributions of 
genetic factors, the mode(s) of inheritance and the 
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